Day: January 30, 2021

Johnson & Johnson Announces Single-Shot Janssen COVID-19 Vaccine Candidate Met Primary Endpoints in Interim Analysis of its Phase 3 ENSEMBLE Trial

Healthtimes

Johnson & Johnson (NYSE: JNJ) (the Company) today announced topline efficacy and safety data from the Phase 3 ENSEMBLE clinical trial, demonstrating that the investigational single-dose COVID-19 vaccine in development at its Janssen Pharmaceutical Companies met all primary and key secondary endpoints. The topline safety and efficacy data are based on 43,783 participants accruing 468 symptomatic cases of COVID-19. The Phase 3 ENSEMBLE study is designed to evaluate the efficacy and safety of the Janssen COVID-19 vaccine candidate in protecting moderate to severe COVID-19, with co-primary endpoints of 14 days…

Pin
Share
Tweet
0 Shares
Read More

Seven things to know about COVID-19 variants in Africa

Healthtimes

New COVID-19 variants have emerged in Africa as the continent records anew peak in infections. While virus mutations are not unusual, those that are more infectious are worrisome.Professor Francisca Mutapi, Professor in Global Health Infection and Immunity, University of Edinburgh,explains the implications of SARS-CoV-2 variants and what African countries can do to respond. Why do viruses mutate, and should we be worried about SARS-CoV-2 variants? Viruses mutate as they replicate. Replication requires that the virus’s genetic information is copied. But this copying is not accurate. It produces mistakes such as…

Pin
Share
Tweet
0 Shares
Read More